About this Presentation
Osteoporosis is a potentially life-threatening condition that is preventable. There are several very different medications available and the consequences of cessation of each therapy needs to be well understood. Continuation therapy is now strongly advised for patients who have ceased denosumab in order to reduce the risk of vertebral fractures.
About the Expert
Prof Peter Ebeling AO
Professor Peter Ebeling AO is Head of the Department of Medicine in the School of Clinical Sciences at Monash Health. He was also inaugural Director of the Australian Institute of Musculoskeletal Science (AIMSS).
Professor Ebeling was Associate Editor of Journal of Bone and Mineral Research from 2008-2012. He currently serves on the Editorial Board of Osteoporosis International and is Editor of Clinical Endocrinology (Oxf) and is Editor-in-Chief of JBMR Plus. He is Medical Director of Osteoporosis Australia; Board Member, International Osteoporosis Foundation; Past-President, Endocrine Society of Australia; Past-President of the Australian and New Zealand Bone and Mineral Society; and Councillor, American Society of Bone and Mineral Research.
